Trial Profile
Phase I-II Study of Palliative Treatment With Nimotuzumab as a Second, Third Line or More of Treatment for Advanced or Metastatic Cervical Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jun 2019
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Apr 2014 New trial record